1. , Bone-marrow haematopoietic-stem-cell niches. Nature Rev Immunol 2006; 6:93–106.
2. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276:71–4.
3. , , , et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143–7.
4. , , In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008; 26:2287–99.
5. , , , et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society fo Cellular Therapy position statement. Cytotherapy. 2006; 8:315–17.
6. , , , , The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD 105). Biochem Biophys Res Commun 1999; 265:134–9.
7. , , , The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem Biophys Res Commun 2001; 289:519–24.
8. , , , , Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998; 176:57–66.
9. , Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol 2000; 28:875–84.
10. , , , Circulating mesenchymal stem cells. Int J Biochem Cell Biol 2004; 36:585–97.
11. , Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105:1815–22.
12. , Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:321–34.
13. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 2006; 69:1–9.
14. , , , , Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 2007; 48:1283–9.
15. , , Biologic characteristics of mesenchymal stromal cells and their clinical applications in pediatric patients. J Pediatr Hematol Oncol 2008; 30:301–9.
16. , , , et al. Ischemic rat brain extracts induce human bone marrow stromal cell growth factor production. Neuropathology 2002; 22:275–9.
17. , , Immunoregulatory function of mesenchymal stem cells. Eur J Immunol. 2006; 36:2566–73.
18. , , , Treatment of inflammatory diseases with mesenchymal stem cells. Inflammation Allergy–Drug Targets 2009; 8:110–23.
19. , , , et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30:42–8.
20. , , , et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99:3838–43.
21. , , , , Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatability complex. Scand J Immunol 2003; 57:11–20.
22. , , , , Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003; 75:389–97.
23. , , , et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102:3837–44.
24. , , , et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004; 60:307–15.
25. , , , et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106:1755–61.
26. , , , et al. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implications for MS. Ann Neurol 2010; 68:540–5.
27. , , , et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101:3722–9.
28. , , , , Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005; 105:2821–7.
29. , , , , Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171:3426–34.
30. , , , et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103:4619–21.
31. , , , et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005; 105:2214–19.
32. , , , Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76:1208–13.
33. , , , et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110:3691–4.
34. , , , et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007; 84:231–7.
35. , , , et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007; 61:219–27.
36. , , , et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107:367–72.
37. , , , et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008; 26:562–9.
38. , , , , Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107:1484–90.
39. , , , et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105:4120–6.
40. , , , et al. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 2007; 83:71–6.
41. , , , et al. Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-lpr/lpr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J Immunol 1994; 152:3119–27.
42. , , , et al. Mesenchymal bone marrow stem cells migrate in CNS lesions in experimental autoimmune encephalomyelitis, differentiate into neuronal and glial line and downregulate EAE (abstract). Neurology 2005; 64(Suppl 1):A407.
43. , Use of stem cells for the treatment of multiple sclerosis. Expert Rev Neurotherap. 2007; 7:1189–201.
44. , , , et al. Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol 2005; 195:16–26.
45. , , , et al. Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol 2007; 61:209–18.
46. , , , et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12:47–57.
47. , , , Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol 2007; 82:887–93.
48. , , , , Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16:557–64.
49. , , , et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18:307–16.
50. , , , , Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell depleted haematopoietic stem cells and culture-expanded marrow mesenchymal cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 2002; 118:1128–31.
51. , , , Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 2009; 43:447–54.
52. , , , et al. A randomized controlled clinical study: co-infusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation. Stem Cells Dev 2011;in press.
53. , , , et al. Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hematopoietic stem cell transplants, reduce acute and chronic graft versus host disease: a matched pair analysis (abstract). Bone Marrow Transplant 2002; 29(Suppl 2):S2.
54. , , , et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439–41.
55. , , , et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81:1390–7.
56. , , , et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007; 21:2271–6.
57. , , , et al. Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade i.v. acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. Leukemia, 2008; 22:1256–7.
58. , , , et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579–86.
59. , , , et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15:804–11.
60. , , , et al. Efficacy and safety of ex-vivo cultured adult mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transpl 2011; 17:534–41.
61. , , , et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010; 16:404–12.
62. , , , et al. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study. Cytotherapy 2010; 12:265–8.
63. , , , et al. Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia 2003; 17:474–6.
64. , , , et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106:3009–17.
65. , , , et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106:1913–8.
66. , , , et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361:45–6.
67. , , , et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004; 94:92–5.
68. , , , et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005; 65:321–9.
69. , , , et al. A randomized, double-blind, placebo-controlled, dose-escalation study of entravenous adult human mesenchymal stem cells (Prohymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54:2277–86.
70. , , , et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361:47–9.
71. , , , Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study. Cardiovasc Revasc Med 2011; 12:29–34.
72. , , , et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360:427–35.
73. , , , Combination stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis. Angiology 2010; 61:551–6.
74. , , , et al. Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis. A case report. Ann Intern Med 2010; 153:650–4.
75. , , , et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 2006; 114:2679–84.
76. , Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol 2003; 139:510–6.
77. , , , , Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. Rejuvenation Res 2009; 12:359–66.
78. , , , et al. Repair of large bone defects with the use of autologous bone marrow stromal cells (letter). N Engl J Med 2001; 344:385–6.
79. , , , et al. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage 2002; 10:199–206.
80. , , , et al. Replacement of recipient stromal/mesenchymal cells after bone marrow transplantation using bone fragments and cultured osteoblast-like cells. Biol Blood Marrow Transplant 2004; 10:709–17.
81. , , , et al. Marrow transplantation for infantile hypophosphatemia. J Bone Miner Res 2003; 18:624–36.
82. , , , et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5:309–13.
83. , , , et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99:8932–7.
84. , , , et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis perfecta. Blood 2001; 97:1227–31.
85. , , , et al. Mesenchymal stem cells. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30:215–22.
86. , , , et al. Improvement of liver function in live cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21:1199–205.
87. , , , et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Chrohn's disease: results of a phase I study. Gut 2010; 59:1662–9.
88. , , , et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractroy systemic lupus erythematosus. Arthritis Rheum 2010; 62:2467–75.
89. , , , et al. Allogenic mesenchymal stem cell transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010; 69:1423–9.
90. , , , Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57:874–82.
91. , , , et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010; 28:1099–106.
92. , , , et al. Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy 2006; 8:202–9.
93. , , , Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci 2008; 265:131–5.
94. , , , et al. Ex vivo-expanded autologous bone marrow-derived mesenchymal stromal cells in human spinal cord injury/paraplegia: a pilot study. Cytotherapy 2009; 11:897–911.
95. , , , et al. Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. Neurorehabil Neural Repair 2010; 24:702–8.
96. , , , , A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy 2008; 10:134–9.
97. , , , et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. ALS and other motor neuron disorders. Amyotroph Lateral Scler Other Motor Neuron Diserd 2003; 4:158–61.
98. , , , et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res 2006; 28:523–6.
99. , , , et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp Neurol 2010; 223:229–37.
100. , , , et al. Safety and immunologic effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010; 67:1187–94.
101. , , , et al. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson's disease. Translational Res 2010; 155:62–70.
102. Bone marrow for the brain? Exp Neurol. 2006; 199:16–19.
103. , , , Cell transplantation therapy for stroke. Stroke 2007; 38:817–26.
104. , Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des 2005; 11:1255–65.
105. , , Elusive mechanisms of “stem-cell”-mediated repair of cerebral damage. Exp Neurol 2006; 199:10–15.
106. , Mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair – current views. Stem Cells 2007; 25:2896–902.
107. , , Plasticity and remodeling of brain. J Neurol Sci 2008; 265:97–101.
108. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. J Clin Neurosci. 2009; 16:12–20.
109. , , , , Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc Natl Acad Sci USA 2005; 102:18171–6.
110. , , , et al. Mesenchymal stem cells instruct oligodrogenic fate decision on adult neural stem cells. Stem Cells 2006; 24:2209–19.
111. , , , Remyelination of the spinal cord following intravenous delivery of bone marrow cells. Glia 2002; 39:229–36.
112. , , , , Sciatic nerve regeneration in rats induced by transplantation of in vitro differentiated bone-marrow stromal cells. Eur J Neurosci 2001; 14:1771–6.
113. , , , et al. Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. Cytotherapy 2007; 9:414–26.
114. , , , , Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in a transgenic mouse model of amyotrophic lateral sclerosis. Cytotherapy 2009; 11:299–306.
115. , , , et al. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett 2001; 315:67–70.
116. , , , et al. Migration of neurotrophic factor-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging. Stem Cells 2008; 26:2542–51.
117. , , , et al. Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells. Neurosurgery 2001; 49:1196–204.
118. , Can bone marrow-derived stem cells differentiate into functional neurons? Exp Neurol 2005; 193:273–8.
119. , , , et al. Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation. Neuroreport 2000; 11:3001–5.
120. , , , et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci USA 2002; 99:2199–204.
121. , , , et al. Bone marrow stromal cells enhance differentiation of cocultured neurosphere cells and promote regeneration of injured spinal cord. J Neurosci Res 2003; 72:343–51.
122. , , , et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98:10344–9.
123. , , , The coronary delivery of marrow stromal cells for myocardial regeneration: Pathophysiologic and therapeutic implications. J Thorac Cardiovasc Surg 2001;122(699–705).
124. , , , et al. Implantation of allogeneic mesenchymal stem cells results in improved cardiac performance in a swine model of myocardial infarction (abstract). Bone Marrow Transplant 2002; 29(Suppl 2):S2.
125. , , , et al. Improved heart function with myogenesis and angiogenesis after autologus porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg 2002; 123:1132–40.
126. , , , et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104:3581–7.
127. , , , et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 2007; 110:1362–9.
128. , , , et al. Direct delivery of syngeneic and allogeneic large-scale expanded multipotent adult progenitor cells improves cardiac function after myocardial infarct. Cytotherapy 2007; 9:477–87.
129. , , , et al. Secreted frizzled related protein 2 (sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Nat Acad Sci USA 2007; 104:1643–8.
130. , , , et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100:8407–11.
131. , , , et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Nat Acad Sci USA 2007; 104:11002–7.
132. , , , et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179:1855–63.
133. , , , et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289:F31–F42.
134. , , , et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17:2202–12.
135. , , , et al. Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells 2008; 26:2075–82.
136. , , , et al. Insulin-like growth factor-1 sustains stem cell-mediated renal repair. J Am Soc Nephrol 2007; 18:2921–8.
137. , , , et al. Mesenchymal stem-derived molecules reverse fulminant hepatic failure. PLoS ONE 2007; 2:e941.
138. , , , et al. Bone marrow multipotent mesenchymal stromal cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury. Stem Cells 2008; 26:1307–14.
139. , Response of the donor and recipient cells in mesenchymal cell transplantation to cartilage defect. Microsc Res Tech 2002; 58:14–18.
140. , , , , Bone marrow stromal cell therapy improves femoral bone mineral density and mechanical strength in ovariectomized rats. Cytotherapy 2008; 10:479–89.
141. , , , et al. The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells 2008; 26:1047–55.
142. , , , et al. Mesenchymal stroma cells improve hyperglycemia and insulin deficiency in the diabetic porcine pancreatic microenvironment. Cytotherapy 2008; 10:796–805.
143. , , , Bone marrow mesenchymal stem cell transplantation improves ovarian function and structure in rats with chemotherapy-induced ovarian failure. Cytotherapy 2008; 10:353–63.
144. , , , et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 2003; 5:1028–38.
145. , , , et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA 1998; 95:1142–7.
146. , , , et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA 1995; 92:4857–61.
147. , , Evidence for migration of donor bone marrow stromal cells into recipient thymus after bone marrow transplantation plus bone grafts: A role of stromal cells in positive selection. Exp Hematol 2000; 28:950–60.
148. , , , et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001; 32:1005–11.
149. , , , et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29:244–55.
150. , , , , The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169:12–20.
151. , , , et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 2003; 75:679–85.
152. , , , et al. Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. Transplantation. 2004; 78:503–8.
153. , , , et al. Survival of human mesenchymal stromal cells from bone marrow and adipose tissue after xenogenic transplantation in immunocompetent mice. Cytotherapy 2008; 10:784–95.
154. , , , , Distribution of mesenchymal stem cells in the area of tissue inflammation after transplantation of the cell material via different routes. Bull Exp Biol Med 2007; 143:143–6.
155. , , , et al. Comparative analysis of remyelinating potential of focal and intravenous administration of autologous bone marrow cells into the rat demyelinated spinal cord. Glia 2003; 44:111–8.
156. , , , et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65:3307–18.
157. , , , et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol 1999; 27:1675–81.
158. , , , et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol 2005; 33:819–27.
159. , , , et al. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 2002; 46:704–13.
160. , , , et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006; 54:2605–15.
161. , , , et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis 2008; 67:741–9.
162. , , , et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxf) 2007; 46:403–8.
163. , , , et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 2008; 67:443–9.
164. , , , et al. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis. Bone Marrow Transplant 2005; 36:1053–63.
165. , , , , Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Mult Scler 2010; 16:909–18.
166. , , , et al. Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implications for assessment of disease activity and treatment. J Neuroimmunol 2008; 199:142–50.
167. , , Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 2008; 10:320–30.
168. , , , , The influence of freezing and storage on the characteristics and functions of human mesenchymal stromal cells isolated for clinical use. Cytotherapy 2007; 9:328–37.
169. , , , Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy 2009; 11:129–36.
170. , , The effect of delivery via narrow-bore needles on mesenchymal cells. Regenerat Med 2009; 4:49–64.
171. , , Autologous mesenchymal bone marrow stem cells: practical considerations. J Neurol Sci 2008; 265:111–5.
172. , , , et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Translat Med 2009:7:29.
173. , , , et al. Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult Scler 2009; 15:644–6.
174. , , Myelin repair: the role of stem and precursor cells in multiple sclerosis. Phil Trans R Soc Lond B Biol Sci 2008; 363:171–83.
175. , , , et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Iran J Immunol 2007; 4:50–7.
176. , , , et al. bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J Neuroimmunol 2010; 227:185–9.
177. , , , Encephalopathy, stroke and myocardial infarction with DMSO use in stem cell transplantation. Neurology 2007; 68:859–61.
178. , , , et al. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologia (Budap) 2007; 92:1208–15.
179. , , , et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol 2007; 18:846–58.
180. , , , et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007; 21:1733–8.
181. , , , et al. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant 2006; 37:1051–9.
182. , , , et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008; 112:532–41.
183. , , , et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008; 22:593–9.
184. , Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood 2004; 103:2892–9.
185. , , , et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004; 23:5095–8.
186. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer 1999; 35:1941–53.
187. , , , et al. Gastric cancer originating from bone marrow-derived cells. Science 2004; 306:1568–1571.
188. , , , et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25:371–9.
189. , , , et al. Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007; 67:9142–9.
190. , , , et al. Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture. Cytotherapy 2005; 7:509–19.
191. , , , et al. Spontaneous human adult stem cell transformation. Cancer Res 2005; 65:3035–9.
192. , , , et al. Biological characterization of long-term cultured human mesenchymal stem cells. Arch Pharm Res 2008; 32:117–26.
193. , , , et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009; 69:5331–9.
194. , , , et al. The (in)auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 2008; 10:657–67.
195. , , , et al. PML-RARα is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL survival. Blood 2004; 103:1815–22.
196. , , , et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557–65.
197. , The CAMMS223 Study Group. Efficacy of alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis: analysis after two years of study CAMMS223 (S12.004). Neurology 2007; 68(Suppl 1):A100.
198. . TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53:457–65.
199. , , , et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a. Ann Neurol 2003; 53:718–24.
200. , , , et al. New diagnostic criteria for multiple sclerosis. Application in first demyelinating episode. Neurology 2003; 60:27–30.
201. , , , et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010; 16:503–10.